Conciseness

The body is dense with high-value, non-obvious material — tool tables, real query examples, KEGG IDs with enzymes, and verified caveats (e.g., 'classification can come back as an empty array'). Minor over-explanation keeps it from a 5: the opening 'Distinct from general metabolomics...' paragraph and parts of the Reasoning Strategy restate biology Claude largely knows.

Actionability

Concrete, executable tool calls with real parameters and outputs appear in every phase (e.g., 'SwissLipids_search(query="PC(16:0/18:1)") → entity_id "SLM:000088148"' and the verified FASN gene lookup). Not a 5 because a few tools used in the workflow ('PubChem_get_CID_by_compound_name', 'LipidMaps_search_by_formula') are absent from the Core Tools table and have no example output.

Workflow Clarity

The 5-phase pipeline (identity → classification → pathway → disease → report) is clearly sequenced with an ASCII diagram, and failure-recovery routes are documented ('If name search fails, try PubChem', 'fall back to LIPID MAPS'). Not a 5 because explicit validation checkpoints are missing — e.g., no step to confirm a returned LMSP ID's exact mass against the observed m/z before proceeding.

Progressive Disclosure

The single 200-line SKILL.md is well-sectioned (When to Use, Core Tools, Workflow, Limitations) but has no bundle files, so content that belongs at one level of depth is inlined: the 8-row KEGG pathway table and the lipid class enrichment script are prime candidates for a references/ file. This matches 'some structure but content that should be separate is inline' rather than the good-split anchor at 4.

Specificity

The description lists several concrete actions — 'lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis' — grounded in named data sources (LIPID MAPS, HMDB, KEGG/Reactome, PubChem). Not a 5 because the leading phrase 'Lipid analysis' is generic and the full capability set (classification, gene/protein lookups, literature) is only implied by the resource list rather than stated as actions.

Completeness

It explicitly answers both questions: the 'what' is lipid analysis and lipid-disease associations using the named databases, and the 'when' is the explicit clause 'Use for lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis (cardiovascular, diabetes, NAFLD)'. Both are concrete and explicit, matching the top anchor.

Trigger Term Quality

Good natural keyword coverage: 'lipid identification', 'pathway mapping', 'sphingolipid', 'eicosanoid', 'steroid', 'fatty acid', 'cardiovascular', 'diabetes', 'NAFLD'. Not a 5 because the most natural user term 'lipidomics' never appears, nor do 'mass spectrometry' or 'm/z' — phrases a user with lipidomics data would actually say.

Distinctiveness Conflict Risk

The lipid-specific vocabulary (LIPID MAPS, sphingolipid, eicosanoid, steroid lipid pathways) carves a clear niche with minimal conflict risk. Not a 5 because 'HMDB metabolite data' and 'PubChem chemical info' overlap with a general metabolomics skill, and the description does not state that boundary (the body reserves it for tooluniverse-metabolomics).